Cellular therapy against public neoantigens

Neoantigen-targeted therapies have typically been based upon personalized neoantigen-specific vaccines; however, in this issue of JCI, van der Lee et al. describe the development of a potential cellular immunotherapy targeting a "public" neoantigen derived from nucleophosmin 1 (NPM1), whic...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2019-02, Vol.129 (2), p.506-508
Main Author: Armistead, Paul M
Format: Article
Language:English
Subjects:
Amino acids
Antigens
Apoptosis
Avidity
Biochemistry
Biomedical research
Cell therapy
Cloning
Conflicts of interest
Gene expression
Gene mutation
Humans
Immunology
Immunotherapy
Leukemia
Leukemia, Myeloid, Acute
Lung cancer
Lymphocytes
Lymphocytes T
Mass spectrometry
Melanoma
Mutation
Neoantigens
Nuclear Proteins
Peptides
Scientific imaging
T cells
Tumor antigens
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoantigen-targeted therapies have typically been based upon personalized neoantigen-specific vaccines; however, in this issue of JCI, van der Lee et al. describe the development of a potential cellular immunotherapy targeting a "public" neoantigen derived from nucleophosmin 1 (NPM1), which is mutated in approximately 30% of acute myeloid leukemias (AMLs). The authors use reverse immunology to predict, and biochemically confirm, NPM1-derived neoepitopes (ΔNPM1) and then generate high-avidity T cell clones and retrovirally transduced T cell populations that kill NPM1-mutated AML. This study provides a general approach to adoptive cellular therapy that can be applied to targeting other tumors with public neoantigens.
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI126116